BEIJING, May 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that the Company will participate at the 2010 Shanghai CPhI Exhibition, being held June 2-4, 2010. Sinovac's exhibition booth will be located in Hall E4, No. E4C42. At the exhibition, Sinovac will showcase its commercialized products, including its Healive, Anflu, Panflu and Panflu.1 vaccines.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are excited to participate in the CPhI Exhibition inShanghai, where we will feature our high quality products, such as vaccines against hepatitis A and seasonal influenza. As the exhibition attracts a global audience, we look forward to meeting with current and potential new international distribution partners to explore opportunities to further advance our global distribution strategy."
The Shanghai CPhI Exhibition provides Sinovac and other exhibitors/attendees with the opportunity to gain a better understanding of the global pharmaceutical industry. In 2009, a total of 1,651 exhibitors attended the event, including 127 overseas companies from 16 countries and regions. In addition to the exhibition booths, CPhI also hosted 54 high level conferences and seminars during the event, providing exhibitors and attendees with the opportunity to further communicate and exchange the latest information in the pharmaceutical industry.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.
About CPhI Worldwide
CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 24,000 industry professionals visiting some 1,500 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI. Two sister events, ICSE and P-MEC now run alongside CPhI, a tripartite of events that is considered the must attend event for any individual or organisation within the pharmaceutical manufacturing community. In 2001 CPhI was launched in China. ICSE China was launched in 2005 and P-MEC China in 2006.
For more information, please contact:
Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659
Fax: +86-10-6296-6910
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Media:
Jason Rando
The Ruth Group
Tel: +1-646-536-7025
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.
EN
